Miguel Madrid-Mencia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Miguel Madrid-Mencia has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Vera Pancaldi
Université de Toulouse, INSERM, CNRS, CRCT, Toulouse, France
21 shared publications - Jean-Jacques Fournié
Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, 31037 Toulouse, France
19 shared publications - Frédéric Pont
INSERM
17 shared publications - Jean-Sébastien Hoffmann
Laboratoire de Pathologie, Laboratoire d'excellence Toulouse Cancer, Institut Universitaire du Cancer-Toulouse, Oncopole, Toulouse Cedex, France
17 shared publications - Valerie Bergoglio
Cancer Research Centre of Toulouse, INSERM
17 shared publications - Abdessamad El Kaoutari
Aix Marseille Univ, CNRS, Inserm, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
15 shared publications
Latest Publications
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs